Clinical Trials Logo

Amyloidosis; Systemic clinical trials

View clinical trials related to Amyloidosis; Systemic.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05201911 Completed - Clinical trials for Amyloidosis; Systemic

A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis

AT03-001
Start date: November 30, 2021
Phase: Phase 1
Study type: Interventional

This is a single center Phase 1 study is to evaluate the biodistribution of radiolabeled AT-03 in patients with systemic amyloidosis.

NCT ID: NCT03401372 Completed - Clinical trials for Amyloidosis; Systemic

BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients

Start date: April 21, 2018
Phase: N/A
Study type: Interventional

Survival of intermediate and high-risk primary light chain amyloidosis (pAL) remains poor due to high mortality within 3-6 months of diagnosis. Rapidly effective regimens such as bortezomib, cyclophosphamide and dexamethasone (BCD) still failed to overcome the poor prognosis in very advanced pAL amyloidosis patients. Recently, doxycycline was demonstrated to induce disruption of fibril formation and reduce the number of intact fibrils in transgenic mouse model of pAL amyloidosis. Furthermore, case-control study suggested that adjuvant oral doxycycline could improve response and survival in cardiac pAL amyloidosis, which necessities further confirmation through a randomized trial. Therefore, we designed a multi-center randomized open-label controlled study to investigate the efficacy and safety of co-administration of oral doxycycline with BCD regimen in treatment-naïve patients with Mayo stage II-III pAL amyloidosis. The primary outcome progression-free survival, and secondary endpoints including overall survival, hematologic response, organ response and toxicity of doxycycline will be evaluated.